BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
03 Maio 2023 - 9:00PM
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and
cell-derived therapeutics for the treatment of cardiovascular and
pulmonary diseases, today announced it will report its financial
results for the three months ended March 31, 2023 and provide a
corporate update by conference call on Wednesday, May 10, 2023 at
4:30 PM ET. Following management’s formal remarks, there will be a
question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10178872/f96d986c90. Please
note that registered participants will receive their dial-in number
upon registration. For those who have not registered, to listen to
the call by phone, interested parties within the U.S. should call
1-833-316-0559 and international callers should call
1-412-317-5730. All callers should dial in approximately 10 minutes
prior to the scheduled start time and ask to be joined into the
BioCardia call. The conference call will also be available through
a live webcast, which can be accessed through the following link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=qLPC1TiA.
A webcast replay of the call will be available approximately one
hour after the end of the call through August 10, 2023 at the above
links. A telephonic replay of the call will be available through
May 24, 2023 and may be accessed by calling 1-877-344-7529
(domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada)
by using access code 8791101. About
BioCardia®BioCardia, Inc., headquartered in
Sunnyvale, California, is a developer of two biotherapeutic
platforms – the CardiAMP autologous bone marrow derived
mononuclear cell therapy for cardiovascular indications, and the
NK1R+ allogeneic bone marrow derived mesenchymal stem cell
therapies for cardiovascular and pulmonary diseases. These
platforms underly four product candidates, each with the potential
to meaningfully benefit millions of patients. Three of these
investigational therapies are enabled by the Company’s proprietary
biotherapeutic delivery platforms, which the Company also
selectively licenses to other biotherapeutic development firms. For
more information visit www.biocardia.com.
MEDIA CONTACT:Anne Laluc alaluc@biocardia.com
(650) 226-0120
INVESTOR CONTACT:David McClung, Chief Financial
Officerinvestors@biocardia.com (650) 226-0120
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024